A Randomized Trial Comparing Autologous Chondrocyte Implantation with Microfracture

Brian J. Cole


- **Reprints and Permissions**
  - Click here to [order reprints or request permission](http://www.jbjs.org) to use material from this article, or locate the article citation on [jbjs.org](http://www.jbjs.org) and click on the [Reprints and Permissions] link.

- **Publisher Information**
  - The Journal of Bone and Joint Surgery
  - 20 Pickering Street, Needham, MA 02492-3157
  - [www.jbjs.org](http://www.jbjs.org)
I read the recently published article “A Randomized Trial Comparing Autologous Chondrocyte Implantation with Microfracture” by Knutsen et al. (2007;89:2105-12) and I am concerned that they may not be generalizable to the full spectrum of patients who present with cartilage injuries.

The authors reported that the overall two and five-year mean scores did not differ significantly between the two treatment groups. However, subanalyses of the two-year follow-up results demonstrated that treatment of smaller lesions with microfracture yielded better clinical outcomes than did treatment of larger lesions, an effect not observed in the autologous chondrocyte implantation group. Other studies have shown that lesion size can negatively affect clinical outcomes after microfracture, a finding not observed with autologous chondrocyte implantation. Unfortunately, the authors of the current paper failed to elaborate on the effect of defect size in each treatment group.

Furthermore, the study did not assess the use of microfracture or autologous chondrocyte implantation in the trochlea. Cartilage defects in the patellofemoral joint pose a significant challenge for treatment. The results in one study of microfracture suggest that hyaline-like repairs were less likely to fail. While the results from this study provide a benchmark with which results from other studies will be compared, they should be confirmed with additional well-designed studies evaluating defect size, location, and histological findings at an even more comprehensive level.

Brian J. Cole, MD
Rush University Medical Center, 1272 West Harrison Avenue, Suite 1063, Chicago, IL 60612, e-mail: bcole@rushortho.com

Disclosure: In support of his research for or preparation of this work, the author received, in any one year, outside funding or grants in excess of $10,000 from Genzyme. Neither he nor a member of his immediate family received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the author, or a member of his immediate family, is affiliated or associated.

References


While the results from this study cannot be generalized to the full spectrum of patients who present with cartilage injuries, we reported the size and location of the defects and clinical data for the enrolled patients. Only defects on the weight-bearing medial and lateral femoral condyles were included, and that has to be considered when our results are interpreted. Far more patients would have been needed in our study to justify stratification into several subgroups. Furthermore, the fact that our cohort of patients had relatively large chronic defects has to be kept in mind. Clearly, there is a need for additional studies. Even longer follow-up of our cohort is needed, and we are aware of other ongoing randomized trials that could increase the evidence base in this difficult field.

Our group reported the two-year results in 2004. We reported that patients with a lesion of >4 cm² had significantly better clinical results following microfracture than...